食管癌是最常见的恶性肿瘤之一，中药复方食道通结方治疗食管癌临床疗效确切。实验研究发现其能下调食管癌细胞中STAT3、Bcl-2蛋白的表达，上调Bax蛋白的表达，同时可下调脂筏上Caveolin-1和EGFR的表达。脂筏作为受体聚集的平台，在信号转导中发挥重要作用，脂筏相关蛋白Caveolin-1在食管癌发生发展的过程中扮演着癌基因的角色。因此我们推测食道通结方的抑瘤作用可能与影响脂筏上Caveolin-1的表达密切相关。本研究从中药复方的整体性作用出发，以脂筏相关蛋白Caveolin-1为切入点，通过构建沉默和过表达Caveolin-1的食管癌细胞株，经过体内外实验，研究食道通结方抑制食管癌细胞增殖、促进凋亡与Caveolin-1调控EGFR/STAT3信号通路的相关性，寻找食道通结方治疗食管癌多靶点、多环节作用的关键点，为临床应用提供强有力的实验依据。

Esophageal cancer is one of the most common malignant tumors. The traditional Chinese medicine compound Shidao Tongjie Decoction is effective in the treatment of esophageal cancer. The experimental study found that it can down-regulate the expression of STAT3, Bcl-2 and other proteins in esophageal cancer cells, up-regulate the expression of Bax and other proteins, and found that the expression of Caveolin-1 and EGFR on lipid rafts can be down-regulated. As a platform for receptor aggregation, lipid rafts play an important role in signal transduction. The lipid raft-related protein Caveolin-1 plays an oncogene role in the development of esophageal cancer. It is speculated that Shidao Tongjie Decoction may inhibit the growth of esophageal cancer cells by regulating EGFR/STAT3 signaling pathway through Caveolin-1. In this study, the lipid-related protein Caveolin-1 was used as the entry point to construct a silent expression and over-expressing Caveolin-1 cell line. From the holistic effect of the traditional Chinese medicine compound, the esophageal cancer can inhibit the proliferation of esophageal cancer cells by in vitro and in vivo experiments. To promote the correlation between apoptosis and Caveolin-1 regulation of EGFR/STAT3 signaling pathway, and to find the key points of Shidao Tongjie Decoction in the treatment of esophageal cancer with multiple targets and multiple links, and provide a strong experimental basis for clinical application.